HUMA
Humacyte IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$134.74M
P/E Ratio
—
EPS
$-0.26
Beta
2.10
52W High
$2.93
52W Low
$0.55
50-Day MA
$1.00
200-Day MA
$1.50
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
23.81
PEG Ratio
—
About Humacyte Inc
Humacyte Inc (HUMA) is a leading biotechnology company focused on transforming vascular and regenerative medicine through its development of innovative human acellular vessels (HAVs). By addressing the urgent clinical needs for vascular reconstruction and the treatment of chronic diseases, Humacyte aims to deliver off-the-shelf solutions that enhance patient outcomes and reduce healthcare costs. Leveraging its advanced technology platform, the company is well-positioned to lead advancements in transplantation and tissue engineering, ultimately making a substantial impact on the future of medical therapies.
Fundamentals
| Revenue (TTM) | $2.04M |
| Gross Profit (TTM) | $-76.37M |
| EBITDA | $-100.09M |
| Operating Margin | -6603.00% |
| Return on Equity | -249.80% |
| Return on Assets | -52.80% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.02 |
| Price-to-Book | 46.67 |
| Price-to-Sales (TTM) | 66.12 |
| EV/Revenue | 78.24 |
| EV/EBITDA | 4.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $222.02M |
| Float | $190.86M |
| % Insiders | 14.15% |
| % Institutions | 25.28% |
Analyst Ratings
Consensus ($5.39 target)
1
Strong Buy5
Buy1
HoldData last updated: 4/8/2026